HVIVO PLC — Board/Management Information 2017

Jun 20, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4848I

hVIVO plc

20 June 2017

For immediate release 7.00am: 20 June 2017

HVIVO PLC

("hVIVO" or the "Company")

Board Change

hVIVO plc (AIM: HVO), a specialty biopharma company with discovery and clinical testing capabilities, is pleased to announce the appointment of Dr Trevor Phillips as a Non-Executive Director, with immediate effect.

Trevor has over thirty years' of experience within the pharmaceutical industry, including extensive international drug development and corporate development responsibilities.  He was previously Chief Operations Officer and President of US Operations, as well as a member of the Board, at Vectura Group plc, a FTSE 250 company listed on the London Stock Exchange focused on respiratory diseases.  Subsequent to joining Vectura in 2010, Trevor played an integral leadership role in the company's successful development, including the acquisition of Activaero GmbH in 2014 and the merger with Skyepharma plc in 2016.   

Prior to joining Vectura, Trevor held the roles of Chief Executive Officer and Chief Operating Officer at Critical Therapeutics, Inc. (now Chiesi USA, Inc.), a US listed specialty pharmaceutical company.  He has also held senior management positions at Sepracor, Inc. (now Sunovion Pharmaceuticals, Inc.), Accenture plc and GlaxoWellcome plc (now GlaxoSmithKline plc).  Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986.  He was awarded an MBA from Henley Management College in 1997.

Jaime Ellertson, Non-Executive Chairman, commented:

"I would like to welcome Dr Trevor Phillips to hVIVO. Trevor brings extensive respiratory drug development and commercialisation experience to hVIVO, which will play a vital role in guiding our partnering and collaboration strategies in respiratory and infectious diseases.  We believe Trevor will strengthen the Board as we progress our precision medicine based inventions and products forward towards commercialisation."

Dr Trevor Phillips, aged 56, is a director/partner or has been a director/partner of the following companies/partnerships during the previous five years:

Current

Prostratex Limited

Previous

Andaris (DDS) Limited
Andaris Group Limited
Innovata Biomed Limited
Innovata Limited
Microshot Limited
Protosome Limited
Qdose Limited
Quadrant Bioresources Limited
Quadrant Drug Delivery Limited
Quadrant Healthcare (UK) Limited
Quadrant Healthcare Limited
Quadrant Holdings Cambridge Limited
Quadrant Technologies Limited
Quadrant Trustee Limited
Skyepharma Limited
Vectura Delivery Devices Limited
Vectura Group Investments Limited
Vectura Group plc
Vectura Limited

Dr Trevor Phillips does not hold any ordinary shares in hVIVO plc.

Save for the information disclosed above there is no other information to be disclosed on Dr Trevor Phillips under Schedule 2(g) of the AIM Rules.

For further information please contact:

hVIVO plc	+44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer)
Media Enquiries	+1 919 710 9658
Susan Flood (Head of Marketing)
Numis Securities Limited	+44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell (UK)	+44 203 727 1000
John Capodanno / Evan Smith (US)	+1 212 850 5705

Notes to Editors:

hVIVO plc ("hVIVO"), a specialty biopharma company with discovery and clinical testing capabilities, is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases.  Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health.  Based in the UK, market leader hVIVO has conducted more than 45 clinical studies, inoculated over 2000 volunteers and has three first-in-class therapies currently in development with a growing pre-clinical pipeline.

This information is provided by RNS

The company news service from the London Stock Exchange

END

BOAUKOARBUANAAR